Item 5.07 Submission of Matters to a Vote of Security Holders

On June 24, 2021, Odonate Therapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following proposals, which are described in more detail in the Company's Definitive Proxy Statement on Schedule 14A that was filed with the U.S. Securities and Exchange Commission on June 1, 2021 (the "Proxy Statement"):



   1.  Election of the 5 director nominees named in the Proxy Statement to serve
       until the 2022 Annual Meeting of Stockholders and until their successors
       are duly elected and qualified;


   2.  Ratification of the selection of Baker Tilly US, LLP as the Company's
       independent registered public accounting firm for the year ending December
       31, 2021; and


  3. Advisory approval of the Company's executive compensation.

Only stockholders of record at the close of business on May 7, 2021 (the "Record Date") were entitled to vote at the Annual Meeting. At the close of business on the Record Date, 38,507,109 shares of common stock were issued and outstanding, of which 31,092,157 shares of common stock were present at the Annual Meeting, either in attendance via the live webcast or represented by proxy.

Each of the proposals voted on at the Annual Meeting was approved by the Company's stockholders. The final voting results with respect to each of the proposals are set forth below:

Proposal 1: Election of Directors





Name of Director Nominees      For        Against    Abstain   Broker Non-vote
Kevin Tang                  26,398,235    129,457    27,150       4,537,315
Aaron Davis                 24,272,017   2,256,774   26,051       4,537,315
Craig Johnson               25,752,318    776,268    26,256       4,537,315
Laura Johnson               26,424,455    104,376    26,011       4,537,315
Robert Rosen                26,329,095    199,748    25,999       4,537,315

Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm





   For       Against   Abstain
31,034,528   15,564    42,065

Proposal 3: Advisory Approval of Executive Compensation





   For       Against   Abstain   Broker Non-vote
26,389,172   127,023   38,647       4,537,315

Item 9.01 Financial Statements and Exhibits



(d) Exhibits



Exhibit
  No.                                     Description

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses